U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07331974) titled 'Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity' on Dec. 30, 2025.
Brief Summary: This study is designed as a preliminary investigation to evaluate the weight-loss efficacy and safety of AKM Lab-01 in an overweight or obese population. It is an interventional, radomized, double-blind, placebo-controlled clinical trial. Participants who meet the eligibility criteria will be randomly assigned to receive AKM Lab-01 or a matching placebo. The intervention will be administered once daily for 3 months. Baseline metrics, along with blood, urine, and stool samples, will be collected from participants, be...